EP1024696A4 - Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease - Google Patents
Combination therapy for reducing the risks associated with cardio- and cerebrovascular diseaseInfo
- Publication number
- EP1024696A4 EP1024696A4 EP98957328A EP98957328A EP1024696A4 EP 1024696 A4 EP1024696 A4 EP 1024696A4 EP 98957328 A EP98957328 A EP 98957328A EP 98957328 A EP98957328 A EP 98957328A EP 1024696 A4 EP1024696 A4 EP 1024696A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cardio
- reducing
- combination therapy
- cerebrovascular disease
- risks associated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6269197P | 1997-10-22 | 1997-10-22 | |
US62691P | 1997-10-22 | ||
GBGB9806688.9A GB9806688D0 (en) | 1998-03-27 | 1998-03-27 | Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease |
GB9806688 | 1998-03-27 | ||
PCT/US1998/021901 WO1999020110A1 (en) | 1997-10-22 | 1998-10-16 | Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1024696A1 EP1024696A1 (en) | 2000-08-09 |
EP1024696A4 true EP1024696A4 (en) | 2004-07-14 |
Family
ID=26313383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98957328A Withdrawn EP1024696A4 (en) | 1997-10-22 | 1998-10-16 | Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1024696A4 (en) |
JP (1) | JP2001520174A (en) |
AU (1) | AU753657B2 (en) |
CA (1) | CA2306646A1 (en) |
WO (1) | WO1999020110A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6620834B1 (en) * | 1999-07-02 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
ES2328446T5 (en) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Use of lysosomal acid lipase to treat atherosclerosis and associated diseases |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
CZ302448B6 (en) | 2000-07-20 | 2011-05-25 | Lauras As | Pharmaceutical composition |
WO2002028270A2 (en) * | 2000-10-06 | 2002-04-11 | Probiochem, Llc | The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
US6534540B2 (en) | 2000-10-06 | 2003-03-18 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor |
WO2002094021A1 (en) * | 2000-10-06 | 2002-11-28 | Probiochem, Llc | A combination and method of treatment of cancer utilizing a cox-2 inhibitor and an hmg-coa inhibitor and cystine to enhance glutathione |
AU2002249812B2 (en) | 2000-12-21 | 2005-11-10 | Nicox S.A. | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
JP4611622B2 (en) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | Pharmaceutical composition for improving blood lipid or reducing blood homocysteine |
CA2492781A1 (en) * | 2002-07-11 | 2004-01-22 | Sankyo Company Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
EP2808015A1 (en) | 2005-05-31 | 2014-12-03 | Mylan Laboratories, Inc | Compositions comprising nebivolol |
US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
JP2009514851A (en) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt |
US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
CN104105478A (en) | 2011-10-28 | 2014-10-15 | 维塔利斯公司 | Anti-flush compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671170A1 (en) * | 1994-03-11 | 1995-09-13 | Bristol-Myers Squibb Company | Use of pravastatin for slowing progression coronary artery atherosclerosis |
WO1997032575A1 (en) * | 1996-03-05 | 1997-09-12 | Children's Hospital Medical Center | Mercapto derivatives as inhibitors of cyclooxygenases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6274896A (en) * | 1995-06-06 | 1996-12-24 | Procyte Corporation | Stable copper(i) complexes as active therapeutic substances |
-
1998
- 1998-10-16 CA CA002306646A patent/CA2306646A1/en not_active Abandoned
- 1998-10-16 WO PCT/US1998/021901 patent/WO1999020110A1/en not_active Application Discontinuation
- 1998-10-16 EP EP98957328A patent/EP1024696A4/en not_active Withdrawn
- 1998-10-16 AU AU13612/99A patent/AU753657B2/en not_active Ceased
- 1998-10-16 JP JP2000516533A patent/JP2001520174A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0671170A1 (en) * | 1994-03-11 | 1995-09-13 | Bristol-Myers Squibb Company | Use of pravastatin for slowing progression coronary artery atherosclerosis |
WO1997032575A1 (en) * | 1996-03-05 | 1997-09-12 | Children's Hospital Medical Center | Mercapto derivatives as inhibitors of cyclooxygenases |
Non-Patent Citations (1)
Title |
---|
See also references of WO9920110A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2306646A1 (en) | 1999-04-29 |
WO1999020110A1 (en) | 1999-04-29 |
JP2001520174A (en) | 2001-10-30 |
AU1361299A (en) | 1999-05-10 |
AU753657B2 (en) | 2002-10-24 |
EP1024696A1 (en) | 2000-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0904082A4 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
EG24678A (en) | Combination therapy | |
ZA987844B (en) | Therapeutic combinations. | |
AP2002002661A0 (en) | Combination therapy for oesteoporosis | |
EP0946178A4 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
ZA987843B (en) | Combination therapy. | |
EP1024696A4 (en) | Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease | |
IL127306A0 (en) | Combination therapy | |
IL131692A0 (en) | Car body with body framework | |
GB9700939D0 (en) | Therapy | |
GB9816556D0 (en) | Therapy | |
GB9705200D0 (en) | Well treatment with particles | |
GB9704112D0 (en) | The Sandelver | |
GB9703633D0 (en) | Cancer therapy | |
EP0676185A3 (en) | Individual sauna cabin. | |
GB9806688D0 (en) | Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease | |
GB9621970D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9616804D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9612082D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9806039D0 (en) | Therapy | |
TW331146U (en) | Far infrared healthy cabin | |
TW352126U (en) | Structure improvement for door inside the door | |
TW352786U (en) | Structure for door inside the door | |
GB9704885D0 (en) | Therapy | |
GB9727507D0 (en) | The door mate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000522;LT PAYMENT 20000522;LV PAYMENT 20000522;MK PAYMENT 20000522;RO PAYMENT 20000522;SI PAYMENT 20000522 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040601 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 01N 43/16 A |
|
17Q | First examination report despatched |
Effective date: 20041110 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060210 |